drugset / Trial / NCT00806169

Combined Triple Therapy in Diabetic Retinopathy (DRP)

NCT00806169

Phase 3 Completed 40 enrolled Johann Wolfgang Goethe University Hospital
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of this pilot study was to investigate the effects of an intravitreal combination therapy using triamcinolone and bevacizumab in patients with macular edema due to diabetic retinopathy.

Timeline

Start
2006-04
Primary completion
2008-10
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal
Subject Triamcinolone Other / unclassified 8 mg Intravitreal